Functional role of soluble receptor for advanced glycation end products in stroke

Sung Chun Tang, Yu Chi Wang, Yu I. Li, Hsiao Ching Lin, Silvia Manzanero, Yu Hsuan Hsieh, Simon Phipps, Chaur Jong Hu, Hung Yi Chiou, Yi Shuian Huang, Wei Shiung Yang, Mark P. Mattson, Thiruma V. Arumugam, Jiann Shing Jeng

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Objective-Little is known about the involvement of the soluble form of receptor for advanced glycation end products (sRAGE) in acute ischemic stroke (IS). Here, we aim to identify the role of plasma sRAGE and high mobility group box 1 (HMGB1) in imaging-confirmed IS patients, as well as mice subjected to focal ischemic stroke. Methods and Results-IS patients were recruited and plasma samples were collected for the measurement of sRAGE and HMGB1 after stroke. The relation of sRAGE and HMGB1 with acute IS was also investigated in a C57BL/6J mouse model of focal ischemic stroke and primary cortical neurons subjected to oxygen and glucose deprivation. Plasma levels of sRAGE and HMGB1 were both significantly increased within 48 hours after IS, and the sRAGE level was an independent predictor of functional outcome at 3 months poststroke. Immunoprecipitation assays revealed that the binding of plasma HMGB1 to sRAGE increased progressively after IS both in patients and mice. Administration of recombinant sRAGE significantly reduced infiltrating immune cells and improved the outcome of injury in mice, protected cultured neurons against oxygen and glucose deprivation-induced cell death, and ameliorated the detrimental effect of recombinant HMGB1. Conclusion-Early poststroke plasma sRAGE may play a protective role in IS by capturing HMGB1. Hence, recombinant sRAGE is a potential therapeutic agent in acute IS.

Original languageEnglish
Pages (from-to)585-594
Number of pages10
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume33
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Stroke
Advanced Glycosylation End Product-Specific Receptor
Oxygen
Neurons
Glucose
Inbred C57BL Mouse
Immunoprecipitation
Cell Death
Wounds and Injuries

Keywords

  • animal model
  • HMGB1
  • inflammation
  • ischemic stroke
  • sRAGe

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Tang, S. C., Wang, Y. C., Li, Y. I., Lin, H. C., Manzanero, S., Hsieh, Y. H., ... Jeng, J. S. (2013). Functional role of soluble receptor for advanced glycation end products in stroke. Arteriosclerosis, Thrombosis, and Vascular Biology, 33(3), 585-594. https://doi.org/10.1161/ATVBAHA.112.300523

Functional role of soluble receptor for advanced glycation end products in stroke. / Tang, Sung Chun; Wang, Yu Chi; Li, Yu I.; Lin, Hsiao Ching; Manzanero, Silvia; Hsieh, Yu Hsuan; Phipps, Simon; Hu, Chaur Jong; Chiou, Hung Yi; Huang, Yi Shuian; Yang, Wei Shiung; Mattson, Mark P.; Arumugam, Thiruma V.; Jeng, Jiann Shing.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 33, No. 3, 03.2013, p. 585-594.

Research output: Contribution to journalArticle

Tang, SC, Wang, YC, Li, YI, Lin, HC, Manzanero, S, Hsieh, YH, Phipps, S, Hu, CJ, Chiou, HY, Huang, YS, Yang, WS, Mattson, MP, Arumugam, TV & Jeng, JS 2013, 'Functional role of soluble receptor for advanced glycation end products in stroke', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 3, pp. 585-594. https://doi.org/10.1161/ATVBAHA.112.300523
Tang, Sung Chun ; Wang, Yu Chi ; Li, Yu I. ; Lin, Hsiao Ching ; Manzanero, Silvia ; Hsieh, Yu Hsuan ; Phipps, Simon ; Hu, Chaur Jong ; Chiou, Hung Yi ; Huang, Yi Shuian ; Yang, Wei Shiung ; Mattson, Mark P. ; Arumugam, Thiruma V. ; Jeng, Jiann Shing. / Functional role of soluble receptor for advanced glycation end products in stroke. In: Arteriosclerosis, Thrombosis, and Vascular Biology. 2013 ; Vol. 33, No. 3. pp. 585-594.
@article{7856407b669b4276a82641c237a56dd3,
title = "Functional role of soluble receptor for advanced glycation end products in stroke",
abstract = "Objective-Little is known about the involvement of the soluble form of receptor for advanced glycation end products (sRAGE) in acute ischemic stroke (IS). Here, we aim to identify the role of plasma sRAGE and high mobility group box 1 (HMGB1) in imaging-confirmed IS patients, as well as mice subjected to focal ischemic stroke. Methods and Results-IS patients were recruited and plasma samples were collected for the measurement of sRAGE and HMGB1 after stroke. The relation of sRAGE and HMGB1 with acute IS was also investigated in a C57BL/6J mouse model of focal ischemic stroke and primary cortical neurons subjected to oxygen and glucose deprivation. Plasma levels of sRAGE and HMGB1 were both significantly increased within 48 hours after IS, and the sRAGE level was an independent predictor of functional outcome at 3 months poststroke. Immunoprecipitation assays revealed that the binding of plasma HMGB1 to sRAGE increased progressively after IS both in patients and mice. Administration of recombinant sRAGE significantly reduced infiltrating immune cells and improved the outcome of injury in mice, protected cultured neurons against oxygen and glucose deprivation-induced cell death, and ameliorated the detrimental effect of recombinant HMGB1. Conclusion-Early poststroke plasma sRAGE may play a protective role in IS by capturing HMGB1. Hence, recombinant sRAGE is a potential therapeutic agent in acute IS.",
keywords = "animal model, HMGB1, inflammation, ischemic stroke, sRAGe",
author = "Tang, {Sung Chun} and Wang, {Yu Chi} and Li, {Yu I.} and Lin, {Hsiao Ching} and Silvia Manzanero and Hsieh, {Yu Hsuan} and Simon Phipps and Hu, {Chaur Jong} and Chiou, {Hung Yi} and Huang, {Yi Shuian} and Yang, {Wei Shiung} and Mattson, {Mark P.} and Arumugam, {Thiruma V.} and Jeng, {Jiann Shing}",
year = "2013",
month = "3",
doi = "10.1161/ATVBAHA.112.300523",
language = "English",
volume = "33",
pages = "585--594",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Functional role of soluble receptor for advanced glycation end products in stroke

AU - Tang, Sung Chun

AU - Wang, Yu Chi

AU - Li, Yu I.

AU - Lin, Hsiao Ching

AU - Manzanero, Silvia

AU - Hsieh, Yu Hsuan

AU - Phipps, Simon

AU - Hu, Chaur Jong

AU - Chiou, Hung Yi

AU - Huang, Yi Shuian

AU - Yang, Wei Shiung

AU - Mattson, Mark P.

AU - Arumugam, Thiruma V.

AU - Jeng, Jiann Shing

PY - 2013/3

Y1 - 2013/3

N2 - Objective-Little is known about the involvement of the soluble form of receptor for advanced glycation end products (sRAGE) in acute ischemic stroke (IS). Here, we aim to identify the role of plasma sRAGE and high mobility group box 1 (HMGB1) in imaging-confirmed IS patients, as well as mice subjected to focal ischemic stroke. Methods and Results-IS patients were recruited and plasma samples were collected for the measurement of sRAGE and HMGB1 after stroke. The relation of sRAGE and HMGB1 with acute IS was also investigated in a C57BL/6J mouse model of focal ischemic stroke and primary cortical neurons subjected to oxygen and glucose deprivation. Plasma levels of sRAGE and HMGB1 were both significantly increased within 48 hours after IS, and the sRAGE level was an independent predictor of functional outcome at 3 months poststroke. Immunoprecipitation assays revealed that the binding of plasma HMGB1 to sRAGE increased progressively after IS both in patients and mice. Administration of recombinant sRAGE significantly reduced infiltrating immune cells and improved the outcome of injury in mice, protected cultured neurons against oxygen and glucose deprivation-induced cell death, and ameliorated the detrimental effect of recombinant HMGB1. Conclusion-Early poststroke plasma sRAGE may play a protective role in IS by capturing HMGB1. Hence, recombinant sRAGE is a potential therapeutic agent in acute IS.

AB - Objective-Little is known about the involvement of the soluble form of receptor for advanced glycation end products (sRAGE) in acute ischemic stroke (IS). Here, we aim to identify the role of plasma sRAGE and high mobility group box 1 (HMGB1) in imaging-confirmed IS patients, as well as mice subjected to focal ischemic stroke. Methods and Results-IS patients were recruited and plasma samples were collected for the measurement of sRAGE and HMGB1 after stroke. The relation of sRAGE and HMGB1 with acute IS was also investigated in a C57BL/6J mouse model of focal ischemic stroke and primary cortical neurons subjected to oxygen and glucose deprivation. Plasma levels of sRAGE and HMGB1 were both significantly increased within 48 hours after IS, and the sRAGE level was an independent predictor of functional outcome at 3 months poststroke. Immunoprecipitation assays revealed that the binding of plasma HMGB1 to sRAGE increased progressively after IS both in patients and mice. Administration of recombinant sRAGE significantly reduced infiltrating immune cells and improved the outcome of injury in mice, protected cultured neurons against oxygen and glucose deprivation-induced cell death, and ameliorated the detrimental effect of recombinant HMGB1. Conclusion-Early poststroke plasma sRAGE may play a protective role in IS by capturing HMGB1. Hence, recombinant sRAGE is a potential therapeutic agent in acute IS.

KW - animal model

KW - HMGB1

KW - inflammation

KW - ischemic stroke

KW - sRAGe

UR - http://www.scopus.com/inward/record.url?scp=84874378856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874378856&partnerID=8YFLogxK

U2 - 10.1161/ATVBAHA.112.300523

DO - 10.1161/ATVBAHA.112.300523

M3 - Article

C2 - 23288172

AN - SCOPUS:84874378856

VL - 33

SP - 585

EP - 594

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 3

ER -